Novel Biomaterial for Improved and Cost efficient Wound Healing
Wound treatment is a major healthcare cost for all developed countries. The global market for advanced wound care products was projected to be $ 3 billion in 2012, with an annual growth above 10% and representing one of the leadin...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BIOCURE
Novel Biomaterial for Improved and Cost efficient Wound Heal...
71K€
Cerrado
WOUNDCOM
The first bioactive wound dressing exploiting the unique w...
4M€
Cerrado
IPT-2012-0602-300000
FIBRODRESS: Desarrollo de un apósito bioactivo basado en fib...
2K€
Cerrado
PID2020-112737RB-I00
DISEÑO DE UN SISTEMA AVANZADO MULTIFUNCIONAL PARA LA LIBERAC...
110K€
Cerrado
PATCHED
Microfabricated hydrogel based complex patch with time depen...
150K€
Cerrado
PHAS
Development of a new generation of bioengineered bandages
191K€
Cerrado
Información proyecto BIOCURE
Duración del proyecto: 29 meses
Fecha Inicio: 2016-02-05
Fecha Fin: 2018-07-31
Líder del proyecto
Innovasjon Norge
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
2M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Wound treatment is a major healthcare cost for all developed countries. The global market for advanced wound care products was projected to be $ 3 billion in 2012, with an annual growth above 10% and representing one of the leading medical product sectors. However, this represents only some 15-20% of the overall cost of wound treatment, where hospitalisation and nurse time represent the remaining costs.
BIOVOTEC aims to pursue a major market opportunity by developing a novel biomaterial based cost-effective wound dressings that can be used for initial treatment of all wounds at risk of delayed or non-healing, reducing the incidence of chronic wounds. BIOCURE range products will be safer, potentially more effective, much more easily scalable and significantly lower in cost when compared with the available advanced wound healing products.
BIOCURE is an opportunity for BIOVOTEC to enter the world-wide advanced wound care market and maintain the European competitive position in the growing biotech and wound management sector. The accomplishment of the project objectives will thus represent a significant business opportunity for the two SMEs, with expected sales of over €50 million within 5 years of launch (i.e. 2022). Furthermore, BIOCURE will positively impact clinicians and patients through early stage treatment or resolution of chronic wounds and payers through reduced treatment costs per wound.